Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ampligen + AZT in HIV-related immune dysfunction
NCT00002269Phase 2Completed
- Sponsor
- HEM Pharma Inc.
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rintatolimod in human immunodeficiency virus infection (HIV) (3 arms), sponsored by HEM Pharma Inc. Primary endpoint: Absolute number of T4 cells. Status: completed.
02
Drugs
rintatolimod
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002269.